Financial Calendar 2015
11 Feb - Half Year Results
12 Aug - Full Year Results
15 Oct - AGM
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
Investor Contact
Mark Dehring
Mark Dehring
Head of Investor Relations
Phone: +613 9389 3407
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email News Alert.

CSL Share Price

Visit our CSL Share Price page to access the quote table and price chart.

About CSL

CSL Limited has over 13,000 staff in more than 27 countries. We produce many life-saving and life-enhancing medicines that enable thousands of people around the world to lead normal healthy lives. Our headquarters is in Australia and we have substantial manufacturing operations in the US, Germany and Switzerland.

CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent a range of human medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself.

ASX Releases

Australia’s Innovation System Could Deliver More
Australia’s System of Innovation has the potential to deliver significantly more in terms of economic productivity, CSL told a Senate Inquiry in Melbourne today.


CSL completes Novartis influenza vaccine business acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million. More.

Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus. More.

Competitive Advanced Manufacturing - Quite within Reach for Australia
Securing a globally competitive locally-based advanced manufacturing sector is quite within reach for Australia, according to CSL Limited, Australia’s largest biotechnology company. The key is to make a serious, strategic effort to attract footloose global investment, especially targeting innovations and ideas developed in Australia. More.

U.S. FDA Accepts for Review CSL Behring’s BLA for its Novel rVIII-SingleChain Therapy for Patients with Haemophilia A
CSL Limited (ASX:CSL; USOTC: CSLLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review CSL Behring’s Biologics License Application (BLA) for its novel investigational recombinant factor VIII single-chain (rVIIISingleChain) for the treatment of haemophilia A. In the pivotal clinical trial, rVIIISingleChain met all primary endpoints. More.

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at
ISTH Congress

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that CSL Behring will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of investigational and branded products at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress being held in Toronto June 20 through 25. The presentations will include pivotal trial data for two of its late-stage recombinant products – its novel recombinant factor VIII SingleChain (rVIII-SingleChain) compound for hemophilia A and its long-acting recombinant factor IX albumin fusion protein (rIX-FP) for hemophilia B. More.

Gordon Naylor to lead CSL’s Global Influenza Vaccine Business
CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Gordon Naylor will lead CSL’s new global influenza vaccine business, which is planned for launch at the start of 2016. Mr Naylor is currently the Company’s Chief Financial Officer and has held executive management responsibility for CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012. More.

European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients
CSL Behring announced today that the European Medicines Agency (EMA) has started the Centralized Procedure for reviewing the company's Marketing Authorization Application (MAA) for its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). More.

Half Year Result 2015
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$692 million for the six months ended 31 December 2014, up US$47 million or 7% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 10%. More.

Prior ASX Releases

>> View the ASX Archive

LinkedIn Twitter Facebook Google+